In summary, our in vitro and in vivo data demonstrate that FGFR1 and PLK1 inhibitors constitute a synergistic drug combination and that the FDA‐approved HCQ further enhances cytotoxicity of the treatment in KRAS‐mutant lung cancer (Fig 7G). This evidence concerns the gene FGFR1 and lung cancer.